Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma

Clinical Cancer Research

Volumn 23, Issue 17, 2017, Pages 5101-5111

  Schwaederlé, Maria C ^a   Patel, Sandip P ^a   Husain, Hatim ^a   Ikeda, Megumi ^a   Lanman, Richard B ^b   Banks, Kimberly C ^b   Talasaz, Amir Ali ^b   Bazhenova, Lyudmila ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Guardant Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CIRCULATING TUMOR DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALK GENE; ARTICLE; CANCER PROGNOSIS; CLINICAL FEATURE; DNA DETERMINATION; EGFR GENE; FEMALE; GENETIC VARIATION; GENOMICS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MET GENE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; VERY ELDERLY; ADENOCARCINOMA; BLOOD; CANCER STAGING; CLINICAL TRIAL (TOPIC); GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CIRCULATING TUMOR DNA; CLINICAL TRIALS AS TOPIC; FEMALE; GENOME, HUMAN; GENOMICS; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING;

EID: 85027511861     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2497     Document Type: Article

References (49)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67:7-30.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359:1367-80.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
4. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. Liu ET, editor. PLoS Med 2005; 2:e73.
5. Gazdar AF Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28 Suppl 1:S24-31.
6. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
7. Bonomi PD, Buckingham L, Coon J. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 2007; 13(15 Pt 2):s4606-12.
8. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Cancer Netw JNCCN 2011; 9:1335-41.
9. Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer 2015; 121:631-9.
10. Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, et al. Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim Biophys Acta 2014; 1846:539-46.
11. Bean J, Brennan C, Shih J-Y, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104:20932-7.
12. Husain H, Kosco K, Rose C, Vibat T, Melnikova V, Erlander MG, et al. Kinetic monitoring of EGFR T790M in urinary circulating tumor DNA to predict radiographic progression and response in patients with metastatic lung adenocarcinoma. J Clin Oncol 2015; 33(suppl; abstr 8081). Available from: http://meetinglibrary.asco.org/content/151073-156.
13. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014; 9:1345-53.
14. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883-92.
15. De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, et al. Capturing intratumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol 2014; 25:1729-35.
16. Schwaederlé M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget 2016; 7: 9707-17.
17. Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One 2015; 10:e0140712.
18. McHugh ML Interrater reliability: the kappa statistic. Biochem Medica 2012; 22:276-82.
19. Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, et al. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience 2014; 1:614-23.
20. Goel MK, Khanna P, Kishore J. Understanding survival analysis: KaplanMeier estimate. Int J Ayurveda Res 2010; 1:274-8.
21. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023-31.
22. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511:543-50.
23. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150:1107-20.
24. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009; 6:201-5.
25. Vigneswaran J, Tan Y-HC, Murgu SD, Won BM, Patton KA, Villaflor VM, et al. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget 2016; 7:18876-86.
26. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012; 18:3462-9.
27. Kim ST, Lee W-S, Lanman RB, Mortimer S, Zill OA, Kim K-M, et al. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget 2015; 6:40360-9.
28. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, et al. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 2015; 6: 12809-21.
29. Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res 2016; 22:5772-82.
30. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14: 985-90.
31. Liang DH, Ensor JE, Liu Z-B, Patel A, Patel TA, Chang JC, et al. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients. Breast Cancer Res Treat 2016; 155:139-49.
32. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, et al. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAF V600E mutation. Cancer Discov 2016; 6:1352-65.
33. Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, et al. Real-time genomic characterization utilizing circulating cell-free DNA in patients with anaplastic thyroid carcinoma. Thyroid 2017; 27:81-7.
34. Zill OA, Mortimer SA, Banks KC, Nagy RJ, Chudova D, Jackson C, et al. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. Abstract LBA11501. J Clin Oncol [Internet] 2016 Jun; 34 (18 suppl). Available from: http://bit.ly/2biymcr.
35. Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov 2017; 7:252-63.
36. Rozenblum AB, Ilouze M, Dudnik E, Dvir A, Soussan-Gutman L, Geva S, et al. Clinical impact of hybrid capture-based next-generation sequencing on changes in treatment decisions in lung cancer. J Thorac Oncol 2017; 12:258-68.
37. Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol 2015; 1: 149-57.
38. Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer Amst Neth 2015; 90:509-15.
39. Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376:629-40.
40. Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, et al. Impact of a bio marker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J Natl Cancer Inst 2015; 107, pii: djv253. doi:10.1093/jnci/djv253.
41. Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol 2015; 33:3817-25.
42. Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, et al. Association of bio marker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a metaanalysis. JAMA Oncol 2016; 2:1452-9.
43. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, et al. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther 2016; 15:743-52.
44. Zheng G, Lin M-T, Lokhandwala PM, Beierl K, Netto GJ, Gocke CD, et al. Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing. Cancer 2016; 124:744-53.
45. Sueoka-Aragane N, Katakami N, Satouchi M, Yokota S, Aoe K, Iwanaga K, et al. Monitoring EGFRT790M with plasma DNA from lung cancer patients in a prospective observational study. Cancer Sci 2016; 107:162-7.
46. Del Re M, Tiseo M, Bordi P, D'Incecco A, Camerini A, Petrini I, et al. Contribution of KRAS mutations and c.2369C >T (p. T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget 2017; 8:13611-9.
47. Que D, Xiao H, Zhao B, Zhang X, Wang Q, Xiao H, et al. EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment. Cancer Biol Ther 2016; 17: 320-7.
48. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, et al. Use of liquid biopsies in clinical oncology: pilot experience in 168 patients. Clin Cancer Res 2016; 22:5497-505.
49. Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 2015; 21:3631-9.